Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
试验速览
- 阶段
- 不适用
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Vision loss
研究概览
简要总结
Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia.
Mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. Investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time interval between COVID19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.
详细描述
Investigators will achieved the following data from the participants:
- Demographic
- Past medical/habitual history
- COVID-19 status and related risk factors
- Mucormycosis status and related risk factors
- Ocular examination and imaging
- Follow-up
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed case of Mucormycosis in COVID-19 pandemic
排除标准
- •People with acute or severely ill conditions that prevent them from ophthalmic examination.
- •Patient, or legal representative opposing the pursuit of the research
结局指标
主要结局
Vision loss
时间窗: 3 months
Prevalence of Vision loss in COVID-19 patients with Mucormycosis co-infection
次要结局
- Risk factors(3 months)
研究者
Mohsen Pourazizi
Dr. Mohsen Pourazizi
Isfahan University of Medical Sciences